BEDFORD, Mass. — October 7, 2025 — Leads & Copy — Ocular Therapeutix, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on redefining the retina experience, announced its participation in several scientific conferences in October 2025.
The conferences include the American Academy of Optometry (October 8-11, Boston, Massachusetts), where Trung Tran, OD, will present one-year results from the HELIOS Phase 1 Trial on OTX-TKI in NPDR on October 9. Ocular Therapeutix will also present at Eyecelerator @ AAO 2025 (October 16, Orlando, Florida) with Peter K. Kaiser, MD, presenting. Additionally, Margaret Chang, MD, MS, will present an on-demand poster at the American Academy of Ophthalmology (October 18-20, Orlando, Florida) on Axitinib Intravitreal Hydrogel in Diabetic Retinopathy.
Ocular Therapeutix is developing AXPAXLI™ (OTX-TKI) for retinal diseases and leverages its ELUTYX™ technology in DEXTENZA®, an FDA-approved corticosteroid, and OTX-TIC for glaucoma or ocular hypertension.
Contact: Bill Slattery, Vice President, Investor Relations, bslattery@ocutx.com
Source: Ocular Therapeutix, Inc.
